MetLife Investment Management’s Disc Medicine IRON Stock Holding History

MetLife Investment Management’s Portfolio IRON Stock Details IRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21M	Buy	16,588 +1,523	+10%	+$105K	0.01%	1422
2026 Q1	$963K	Buy	15,065 +1,233	+9%	+$85.6K	﹤0.01%	1415
2025 Q4	$1.1M	Sell	13,832 -90	-0.6%	-$7.61K	0.01%	1372
2025 Q3	$920K	Sell	13,922 -932	-6%	-$55.4K	﹤0.01%	1495
2025 Q2	$787K	Buy	14,854 +1,400	+10%	+$65.8K	﹤0.01%	1444
2025 Q1	$668K	Buy	13,454 +1,322	+11%	+$73.5K	﹤0.01%	1565
2024 Q4	$769K	Buy	12,132 +755	+7%	+$43.7K	﹤0.01%	1558
2024 Q3	$559K	Buy	11,377 +1,735	+18%	+$81.5K	﹤0.01%	1726
2024 Q2	$435K	Buy	9,642 +4,850	+101%	+$165K	﹤0.01%	1799
2024 Q1	$298K	Hold	4,792	–	–	﹤0.01%	1962
2023 Q4	$277K	Hold	4,792	–	–	﹤0.01%	2055
2023 Q3	$225K	Buy	4,792 +598	+14%	+$29.9K	﹤0.01%	2139
2023 Q2	$186K	Buy	+4,194	New	+$149K	﹤0.01%	2322

Other funds holding IRON

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MetLife Investment Management's IRON Position: Q2 2026 in Review

MetLife Investment Management increased its Disc Medicine (IRON) stake by 10% in Q2 2026, buying an estimated $105K and bringing the position to 16,588 shares worth $1.21M. The position accounts for 0.01% of the portfolio, ranked #1422.

MetLife Investment Management first reported a position in IRON in Q2 2023 and has held it in 13 quarters since. 215 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

MetLife Investment Management held 16,588 shares of Disc Medicine worth $1.21M as of Q2 2026.
MetLife Investment Management bought 1,523 Disc Medicine shares in Q2 2026, an estimated $105K.
Disc Medicine made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1422 holding.
MetLife Investment Management first reported a position in Disc Medicine in Q2 2023 and has held it in 13 quarters since.
215 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.